Kiniksa Pharmaceuticals International, plc $KNSA Shares Purchased by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC raised its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 44.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 247,301 shares of the company’s stock after buying an additional 75,864 shares during the quarter. Kiniksa Pharmaceuticals International comprises about 1.5% of Essex Investment Management Co. LLC’s portfolio, making the stock its 9th biggest holding. Essex Investment Management Co. LLC owned about 0.33% of Kiniksa Pharmaceuticals International worth $9,603,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of the stock. Amundi purchased a new stake in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Kiniksa Pharmaceuticals International by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after buying an additional 1,002 shares during the period. Millennium Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. Nordea Investment Management AB raised its holdings in shares of Kiniksa Pharmaceuticals International by 1.6% in the 2nd quarter. Nordea Investment Management AB now owns 130,160 shares of the company’s stock valued at $3,582,000 after buying an additional 2,110 shares during the period. Finally, Cannon Global Investment Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $479,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on KNSA shares. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.33.

Kiniksa Pharmaceuticals International Trading Up 2.9%

Shares of KNSA stock opened at $44.35 on Tuesday. The company has a market cap of $3.36 billion, a P/E ratio of 98.56 and a beta of 0.06. The firm has a fifty day moving average price of $41.88 and a 200 day moving average price of $38.50. Kiniksa Pharmaceuticals International, plc has a 12 month low of $18.12 and a 12 month high of $45.50.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $41.89, for a total value of $502,680.00. Following the completion of the transaction, the chief financial officer directly owned 19,086 shares of the company’s stock, valued at $799,512.54. This represents a 38.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Barry D. Quart sold 2,602 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $45.02, for a total transaction of $117,142.04. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $564,820.92. The trade was a 17.18% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 135,548 shares of company stock valued at $5,675,604. Corporate insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.